Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design

Simons FE(2011)Histamine and H(1)-antihistamines: celebrating a century of progress J Allergy Clin Immunol 128 1139-1150

Simons KJ(1997)Rupatadine, a new potent, orally active dual antagonist of histamine and platelet activating factor (PAF) J Pharmacol Exp Ther 280 114-121

Merlos M(1991)Study of the effects of paf-acheter on human nasal airways Allergy 6 466-471

Giral M(1994)Nasal neutrophilia and esosinophilia induced by challenge with platelet activating factor J Allergy Clin Immunol 2 526-533

Balsa D(1992)Eosinophil chemotactic activity of topical PAF on the human nasal mucosa Eur J Clin Pharmacol 3 295-299

Ferrando R(2013)Platelet-activating factor nasal challenge induces nasal congestion and reduces nasal volume in both healthy volunteers and allergic rhinitis patients Am J Rhinol Allergy 27 1-5

Queralt M(2006)Acoustic rhinometry in the practice of allergy Ann Allergy Asthma Immunol 6 745-751

Puigdemont A(2005)Inhibitory activity of rupatadine on pro-inflammatory cytokine production, relationship with binding affinity Methods Find Exp Clin Pharmacol 27 161-162

Garcia Rafanell J(1996)Dual effect of a new compound, rupatadine, on edema induced by platelet activating factor and histamine in dogs: comparison with antihistamines and PAF antagonists Drug Dev Res 39 12-18

Forn J(2010)Efficacy and tolerability of rupatadine at four times the recommended dose against histamine and PAF induced flare responses and ex vivo platelet aggregation in healthy males Br J Dermatol 163 1330-1332

Simons FE(2011)Histamine and H(1)-antihistamines: celebrating a century of progress J Allergy Clin Immunol 128 1139-1150

Simons KJ(1997)Rupatadine, a new potent, orally active dual antagonist of histamine and platelet activating factor (PAF) J Pharmacol Exp Ther 280 114-121

Merlos M(1991)Study of the effects of paf-acheter on human nasal airways Allergy 6 466-471

Giral M(1994)Nasal neutrophilia and esosinophilia induced by challenge with platelet activating factor J Allergy Clin Immunol 2 526-533

Balsa D(1992)Eosinophil chemotactic activity of topical PAF on the human nasal mucosa Eur J Clin Pharmacol 3 295-299

Ferrando R(2013)Platelet-activating factor nasal challenge induces nasal congestion and reduces nasal volume in both healthy volunteers and allergic rhinitis patients Am J Rhinol Allergy 27 1-5

Queralt M(2006)Acoustic rhinometry in the practice of allergy Ann Allergy Asthma Immunol 6 745-751

Puigdemont A(2005)Inhibitory activity of rupatadine on pro-inflammatory cytokine production, relationship with binding affinity Methods Find Exp Clin Pharmacol 27 161-162

Garcia Rafanell J(1996)Dual effect of a new compound, rupatadine, on edema induced by platelet activating factor and histamine in dogs: comparison with antihistamines and PAF antagonists Drug Dev Res 39 12-18

Forn J(2010)Efficacy and tolerability of rupatadine at four times the recommended dose against histamine and PAF induced flare responses and ex vivo platelet aggregation in healthy males Br J Dermatol 163 1330-1332